CVZ 002
Alternative Names: CVZ-002Latest Information Update: 28 Mar 2023
At a glance
- Originator ReVision Therapeutics
- Class Eye disorder therapies
- Mechanism of Action Lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Stargardt disease
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Stargardt disease in USA (Intravitreous, Injection)
- 19 Feb 2019 CVZ 002 is available for licensing as of 19 Feb 2019. https://revisiontherapeutics.com/
- 01 Feb 2019 Preclinical trials in Stargardt disease in USA (Intravitreous) before February 2019 (ReVision Therapeutics pipeline, February 2019)